{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:25:14Z","timestamp":1794086714794,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020742","name":"State Key Laboratory of Anti-Infective Drug Development","doi-asserted-by":"publisher","award":["2015DQ780357"],"award-info":[{"award-number":["2015DQ780357"]}],"id":[{"id":"10.13039\/100020742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.antiviral.2026.106519","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:54:24Z","timestamp":1788188064000},"page":"106519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Class I capsid assembly modulators induce potent anti-HBV activity through direct viral suppression, innate immune activation and caspase-3-independent clearance of infected hepatocytes"],"prefix":"10.1016","volume":"255","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8336-1589","authenticated-orcid":false,"given":"Pu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0184-8738","authenticated-orcid":false,"given":"Yunfu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.antiviral.2026.106519_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-18339-6","article-title":"The dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators","volume":"15","author":"Askari","year":"2025","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.antiviral.2026.106519_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.antiviral.2026.106519_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01502-23","article-title":"Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level in vivo is dependent on de novo core protein translation","volume":"98","author":"Berke","year":"2024","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106519_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/biom15010062","article-title":"HBV cccDNA: the molecular reservoir of Hepatitis B persistence and challenges to achieve viral eradication","volume":"15","author":"Boonstra","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.antiviral.2026.106519_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.antiviral.2017.11.015","article-title":"The diverse functions of the hepatitis B core\/capsid protein (HBc) in the viral life cycle: implications for the development of HBc-targeting antivirals","volume":"149","author":"Diab","year":"2018","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106519_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/cdd.2008.144","article-title":"Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression","volume":"16","author":"Du","year":"2009","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106519_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106519_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hep4.1804","article-title":"Capsid allosteric modulators enhance the innate immune response in hepatitis B virus-infected hepatocytes during interferon administration","volume":"6","author":"Fukutomi","year":"2022","journal-title":"Hepatol. Commun."},{"issue":"6","key":"10.1016\/j.antiviral.2026.106519_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/13596535251392955","article-title":"A phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel class E capsid assembly modulator, in healthy participants","volume":"30","author":"Gane","year":"2025","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106519_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11901-024-00652-9","article-title":"Perspective on emerging therapies to achieve functional cure of chronic hepatitis B","volume":"23","author":"Gopalakrishna","year":"2024","journal-title":"Curr. Hepat. Rep."},{"issue":"44","key":"10.1016\/j.antiviral.2026.106519_bib11","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.A113.033347","article-title":"The hepatitis B virus HBx protein inhibits caspase 3 activity","volume":"288","author":"Gottlob","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2026.106519_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105196","article-title":"JNJ-64794964 (AL-034\/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV\/HBV mice via non-cytolytic mechanisms","volume":"196","author":"Herschke","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106519_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)00964-3","article-title":"Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with\/without peg-IFN in chronic hepatitis B patients","volume":"77","author":"Hou","year":"2022","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106519_bib14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12072-025-10828-0","article-title":"Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies","volume":"19","author":"Hui","year":"2025","journal-title":"Hepatol. Int."},{"issue":"7","key":"10.1016\/j.antiviral.2026.106519_bib15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","article-title":"Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection","volume":"72","author":"Janssen","year":"2023","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.antiviral.2026.106519_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00420-24","article-title":"Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein","volume":"68","author":"Kornyeyev","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106519_bib17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/HEP.0000000000000428","article-title":"Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation","volume":"78","author":"Kum","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2026.106519_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4049\/jimmunol.178.1.503","article-title":"Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax","volume":"178","author":"Liang","year":"2007","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.antiviral.2026.106519_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/v9080230","article-title":"Interference of apoptosis by hepatitis B virus","volume":"9","author":"Lin","year":"2017","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.antiviral.2026.106519_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.35772\/ghm.2023.01065","article-title":"Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure","volume":"5","author":"McFadden","year":"2023","journal-title":"Glob Health Med"},{"issue":"3","key":"10.1016\/j.antiviral.2026.106519_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/v15030642","article-title":"Hepatitis B virus capsid: the core in productive entry and covalently closed circular DNA formation","volume":"15","author":"Mendenhall","year":"2023","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.antiviral.2026.106519_bib22","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.antiviral.2026.106519_bib23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3390\/biomedicines9111577","article-title":"The hepatitis B virus nucleocapsid-dynamic compartment for infectious virus production and new antiviral target","volume":"9","author":"Niklasch","year":"2021","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.antiviral.2026.106519_bib25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2026.106519_bib24","series-title":"Hepatitis B","author":"Organization","year":"2025"},{"issue":"4","key":"10.1016\/j.antiviral.2026.106519_bib26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","article-title":"Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA","volume":"84","author":"Sells","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.antiviral.2026.106519_bib27","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/jcm11051349","article-title":"Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives","volume":"11","author":"Taverniti","year":"2022","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106519_bib28","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.antiviral.2026.106519_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00722-23","article-title":"Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles","volume":"97","author":"Vanrusselt","year":"2023","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.antiviral.2026.106519_bib30","doi-asserted-by":"crossref","first-page":"21126","DOI":"10.1021\/acs.jmedchem.4c01814","article-title":"The discovery and preclinical profile of ALG-000184, a prodrug of the potent Hepatitis B virus capsid assembly modulator ALG-001075","volume":"67","author":"Vendeville","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2026.106519_bib31","series-title":"Global Hepatitis Report","year":"2024"},{"issue":"11","key":"10.1016\/j.antiviral.2026.106519_bib32","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.01091-13","article-title":"Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly","volume":"57","author":"Wu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2026.106519_bib33","unstructured":"Yuen M-F, et al. A phase I randomized study of a novel HBV capsid assembly modulator, ALG-000184, in participants with chronic HBV infection: effects on safety, HBV DNA and HBsAg levels. Available at: SSRN: https:\/\/ssrn.com\/abstract=5225723orhttps:\/\/doi.org\/10.2139\/ssrn.5225723.."},{"key":"10.1016\/j.antiviral.2026.106519_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)02029-3","article-title":"Viral nucleic acids suppression activity of RO7049389 plus NUC with\/without peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and post-treatment follow-up","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2026.106519_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(25)00293-6","article-title":"ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial","author":"Yuen","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106519_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral activity and pharmacokinetics of the Hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2026.106519_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106446","article-title":"Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: a multicenter clinical trial","volume":"90","author":"Zhang","year":"2025","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2026.106519_bib37","doi-asserted-by":"crossref","first-page":"10411","DOI":"10.2147\/DDDT.S564254","article-title":"Pegylated Interferon-\u03b1-Induced functional cure for special populations with chronic hepatitis B virus infection: current trends, challenges and prospection","volume":"19","author":"Zhang","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106519_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70777","article-title":"GLS4 induces the interferon signaling pathway during Hepatitis B virus (HBV) infection","volume":"98","author":"Zhao","year":"2026","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2026.106519_bib40","series-title":"Antigen Suppression Effect of the Core Protein Allosteric Modulator RO7049389 in AAV-HBV Mice is Accompanied by Transient Upregulation of immune-cell Gene Signatures in the Liver","author":"Zhou","year":"2019"},{"issue":"2","key":"10.1016\/j.antiviral.2026.106519_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 Study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.antiviral.2026.106519_bib41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2023.01.017","article-title":"Eliminating cccDNA to cure hepatitis B virus infection","volume":"78","author":"Zoulim","year":"2023","journal-title":"J. Hepatol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226001786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226001786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:22:44Z","timestamp":1794086564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354226001786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"alternative-id":["S0166354226001786"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106519","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Class I capsid assembly modulators induce potent anti-HBV activity through direct viral suppression, innate immune activation and caspase-3-independent clearance of infected hepatocytes","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106519"}}